Showing results (81-90 of 93) with videos related to
Sort By:
Pageof 10
Blood|June 28, 2007
Relapse risk in patients with malignant diseases given allogeneic hematopoietic cell transplantation after nonmyeloablative conditioningChristoph Kahl, Barry E Storer, Brenda M Sandmaier, et al.Blood|November 19, 2019
Randomized multicenter trial of sirolimus vs prednisone as initial therapy for standard-risk acute GVHD: the BMT CTN 1501 trialJoseph Pidala, Mehdi Hamadani, Peter Dawson, et al.JAMA|November 3, 2011
Long-term outcomes among older patients following nonmyeloablative conditioning and allogeneic hematopoietic cell transplantation for advanced hematologic malignanciesMohamed L Sorror, Brenda M Sandmaier, Barry E Storer, et al.Journal of the National Comprehensive Cancer Network : JNCCN|June 11, 2020
Hematopoietic Cell Transplantation, Version 2.2020, NCCN Clinical Practice Guidelines in OncologyAyman Saad, Marcos de Lima, Sarah Anand, et al.Blood|July 22, 2021
HLA-haploidentical vs matched unrelated donor transplants with posttransplant cyclophosphamide-based prophylaxisMahasweta Gooptu, Rizwan Romee, Andrew St Martin, et al.Blood|January 5, 2017
Low immunosuppressive burden after HLA-matched related or unrelated BMT using posttransplantation cyclophosphamideChristopher G Kanakry, Javier Bolaños-Meade, Yvette L Kasamon, et al.Blood|September 12, 2022
Effective treatment of low-risk acute GVHD with itacitinib monotherapyAaron Etra, Alexandra Capellini, Amin Alousi, et al.Journal of the National Comprehensive Cancer Network : JNCCN|February 15, 2023
NCCN Guidelines® Insights: Hematopoietic Cell Transplantation, Version 3.2022Ayman Saad, Alison Loren, Javier Bolaños-Meade, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 13, 2013
Graft-versus-host disease and graft-versus-tumor effects after allogeneic hematopoietic cell transplantationRainer Storb, Boglarka Gyurkocza, Barry E Storer, et al.The Lancet. Haematology|March 3, 2019
Three prophylaxis regimens (tacrolimus, mycophenolate mofetil, and cyclophosphamide; tacrolimus, methotrexate, and bortezomib; or tacrolimus, methotrexate, and maraviroc) versus tacrolimus and methotrexate for prevention of graft-versus-host disease with haemopoietic cell transplantation with reduced-intensity conditioning: a randomised phase 2 trial with a non-randomised contemporaneous control group (BMT CTN 1203)Javier Bolaños-Meade, Ran Reshef, Raphael Fraser, et al.Pageof 10